Effect of the Weekly Administration of Exenatide LAR or Dulaglutide on the Variability of Blood Pressure and Heart Rate of 24 Hours in Patients With Type 2 Diabetes Mellitus Without Pharmacological Treatment
Phase of Trial: Phase IV
Latest Information Update: 26 Oct 2018
At a glance
- Drugs Dulaglutide (Primary) ; Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 18 Oct 2018 Planned End Date changed from 30 Nov 2018 to 30 Dec 2018.
- 18 Oct 2018 Planned primary completion date changed from 30 Aug 2018 to 30 Dec 2018.
- 31 Aug 2018 Biomarkers information updated